001), indoles (0001), plasma interleukin (IL)-1β (P=0048), IL-6

001), indoles (0.001), plasma interleukin (IL)-1β (P=0.048), IL-6 (P=0.002), tumor necrosis factor-α (P=0.032), renin (P=0.003), aldosterone (P=0.021), and brain-type natri-uretic peptide (P=0.016) levels improved significantly from baseline to 6 months in the probiotic group but not the placebo group. There was a significant improvement in the physical function (P=0.005) and role physical (P=0.019) domains and in the physical component summary (P=0.030) of the Medical Outcomes Study Short-Form (SF)-36 after 24 weeks of treatment in the probiotic group while there was no change in any of

the SF-36 domain in placebo group. There were no adverse events related to the study drug. Conclusions: Over a 6-month period, treatment with probiotic significantly reduced the risk of hospitalization involving overall complications of cirrhosis including HE and significantly improved liver disease severity, systemic inflammation

and HRQOL. (ClinicalTrials.gov GS-1101 manufacturer buy Acalabrutinib number, NCT01110447) Interim results of this study were presented in AASLD 2012 as oral presentation (Hepatology 2012;56(Suppl 255A) Disclosures: The following people have nothing to disclose: Radha K. Dhiman, Baldev S. Rana, Swastik Agrawal, Ashish Garg, Madhu Chopra, Kiran K. Thumburu, Amit Khattri, Samir Malhotra, Ajay K. Duseja, Yogesh K. Chawla Background & Aim: Gastro-esophageal variceal bleeding (VB) is an important complication of portal hypertension (PHT) with mortality of 30-50% within 6 weeks. The recommended therapy

for primary prophylaxis of large varices is beta-blocker therapy (BB) or endoscopic variceal ligation (EVL). However, there are limited options for BB non-responders. VSL#3 is hypothesized to reduce gut translocation and endotoxemia with consequent reduction of portal pressure. We investigated the efficacy of combination of VSL#3 and carvedilol 上海皓元 compared to EVL as primary prophylaxis for non-responders to BB for large varices. Patients and Methods: It was a randomized open labeled active controlled trial.Consecutive cirrhotics with large varices were prospectively enrolled from December 2012. After informed consent, patients were given maximum tolerated dose of carvedilol till heart rate reduced to 55 bpm or adverse-effects developed. After 2 months, repeat HVPG was performed and non-responders (≤ 20% reduction in HVPG) were randomized into carvedilol +VSL#3(Group A) or EVL (Group B) in 1:1 ratio.The primary end-point was onset of first variceal bleed. Secondary end-points were time to bleed and safety profile of drugs. Results: Out of 119 patients, 76 patients underwent repeat HVPG. 42 (55.26 %) were responders and excluded from the study. 34 non- responders were randomized into Groups A (n=17) or B (n=17). The mean CTP and MELD in Group A (6.75 ± 0.856 and 8.20 ± 3.028) and B (7.33 ± 1.496 and 9.85 ± 4.981) were comparable (p> 0.05). The mean carvedilol dose was 11.92 ± 2.05 mg/day and target heart rate achieved in Group A was 58±3 beats per minute.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>